MedTrace Logo

Treatment for Clostridium-difficile Infection With IMM529

NCT03065374 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2019-12-26

No results posted yet for this study

Summary

This study will evaluate the safety and tolerability of IMM-529 together with standard of care (SOC) in patients with Clostridium-difficile Infection.

Conditions

  • Clostridium Difficile Infection
  • Clostridium Difficile Infection Recurrence

Interventions

BIOLOGICAL

IMM-529

IMM-529

OTHER

Placebo

Matching placebo

Sponsors & Collaborators

  • Immuron Ltd.

    lead INDUSTRY

Principal Investigators

  • Neta Tobis · Immuron Limited

  • Jerry Kanellos · Immuron Limited

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-01
Primary Completion
2019-11-07
Completion
2019-11-07

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03065374 on ClinicalTrials.gov